Ask AI
TROP2 TIGIT for NSCLC
TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?

Released: November 19, 2025

Activity

Progress
1
Course Completed

In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:

  • TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan
  • TROP2 ADCS for patients with EGFR-mutated NSCLC
  • TIGIT-targeting agents: domvanalimab, rilvegostomig